Novel CAR-T Attacks New Target in Relapsed LBCL | Anne Kramer, MD, PhD |

แชร์
ฝัง
  • เผยแพร่เมื่อ 1 ม.ค. 2025
  • Dr. Anne Kramer from Stanford University discusses the use of CD22-targeting CAR T-cell therapy for patients who have relapsed following CD19-targeting CAR-T therapy.
    Link to ASH playlist on HTU: healthtree.org...
    ASH Abstract: CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up
    #ASH24 #DLBCL #lymsm
    Follow HealthTree: linktr.ee/Heal...

ความคิดเห็น •